• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic.

作者信息

Kow Chia Siang, Ramachandram Dinesh Sangarran, Hasan Syed Shahzad

机构信息

School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.

School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia.

出版信息

Med Clin (Barc). 2022 Nov 11;159(9):e61. doi: 10.1016/j.medcli.2022.05.016. Epub 2022 Jul 20.

DOI:10.1016/j.medcli.2022.05.016
PMID:35933189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9296499/
Abstract
摘要

相似文献

1
Direct oral anticoagulants (DOAC) for patients with atrial fibrillation during the COVID-19 pandemic.新型冠状病毒肺炎大流行期间心房颤动患者使用直接口服抗凝剂（DOAC）的情况
Med Clin (Barc). 2022 Nov 11;159(9):e61. doi: 10.1016/j.medcli.2022.05.016. Epub 2022 Jul 20.
2
Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).COVID-19 大流行对英格兰全国口服维生素 K 拮抗剂 (VKA) 和直接口服抗凝剂 (DOACs) 处方的影响：一项中断时间序列分析（2019 年 1 月至 2021 年 2 月）。
Curr Med Res Opin. 2022 Jul;38(7):1081-1092. doi: 10.1080/03007995.2022.2078100. Epub 2022 May 30.
3
Impact of COVID-19 on the Prescribing Pattern of Oral Anticoagulants for Atrial Fibrillation After Cardiac Surgery.COVID-19 对心脏手术后房颤患者口服抗凝药物处方模式的影响。
J Cardiovasc Pharmacol Ther. 2022 Jan-Dec;27:10742484221128124. doi: 10.1177/10742484221128124.
4
Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation.采用直接口服抗凝剂预防心房颤动中的脑卒中。
Intern Med J. 2016 Jul;46(7):792-7. doi: 10.1111/imj.13088.
5
Comparative Effectiveness and Safety of Direct Oral Anticoagulants Compared with Warfarin in Patients with Low Bodyweight who have Atrial Fibrillation: A Systematic Review and Meta-analysis.直接口服抗凝剂与华法林在低体重房颤患者中的比较有效性和安全性：系统评价和荟萃分析。
Am J Cardiovasc Drugs. 2024 Mar;24(2):255-271. doi: 10.1007/s40256-024-00628-6. Epub 2024 Feb 22.
6
Author Response: Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Cohort Study.作者回应：口服抗凝剂与非瓣膜性心房颤动患者的痴呆风险：一项基于人群的队列研究。
Neurology. 2023 Oct 17;101(16):729. doi: 10.1212/WNL.0000000000207890.
7
Reader Response: Oral Anticoagulants and the Risk of Dementia in Patients With Nonvalvular Atrial Fibrillation: A Population-Based Cohort Study.读者回应：口服抗凝剂与非瓣膜性心房颤动患者的痴呆风险：一项基于人群的队列研究
Neurology. 2023 Oct 17;101(16):728-729. doi: 10.1212/WNL.0000000000207889.
8
Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study.肾功能与直接口服抗凝剂与华法林在成人房颤患者中的比较效果和安全性：一项多中心观察性研究。
Eur Heart J Qual Care Clin Outcomes. 2023 Sep 12;9(6):621-631. doi: 10.1093/ehjqcco/qcac069.
9
Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.低剂量直接口服抗凝剂用于心房颤动卒中预防的比较安全性和有效性
Am J Med. 2024 Jun;137(6):520-528.e13. doi: 10.1016/j.amjmed.2024.02.005. Epub 2024 Feb 21.
10
Letter by Mayer Regarding Article, "Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants".
Circulation. 2024 Apr 16;149(16):e1109-e1110. doi: 10.1161/CIRCULATIONAHA.123.067538. Epub 2024 Apr 15.

本文引用的文献

1
Effect on Morbidity and Mortality of Direct Oral Anticoagulants in Patients With COVID-19.直接口服抗凝剂对新冠病毒肺炎患者发病率和死亡率的影响。
Am J Cardiol. 2022 May 15;171:174-177. doi: 10.1016/j.amjcard.2022.02.007. Epub 2022 Mar 12.
2
Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry.严重急性呼吸综合征冠状病毒 2 感染和心房颤动患者的死亡风险因素：来自 SEMI-COVID-19 登记处的数据。
Med Clin (Barc). 2022 Nov 25;159(10):457-464. doi: 10.1016/j.medcli.2022.01.008. Epub 2022 Mar 10.
3
Pharmacologic therapeutic options for thromboprophylaxis in COVID-19.2019冠状病毒病血栓预防的药物治疗选择
J Thromb Thrombolysis. 2021 Jan;51(1):29-30. doi: 10.1007/s11239-020-02200-w.
4
Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide.COVID-19 大流行期间的门诊华法林治疗管理：实用指南。
Am J Cardiovasc Drugs. 2020 Aug;20(4):301-309. doi: 10.1007/s40256-020-00415-z.
5
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial.利伐沙班对凝血和炎症生物标志物的影响：X-VeRT试验的事后分析
TH Open. 2020 Jan 23;4(1):e20-e32. doi: 10.1055/s-0040-1701206. eCollection 2020 Jan.